Supplementary Figure S5 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Authors:

Open Access

Predicted Relatlimab Exposures at 160 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adults